The Scorpion Therapeutics spinoff sold rights for two EGFR inhibitors to Pierre Fabre Laboratories and is hoping to become a clinical-stage firm by 2026.

Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not ...

Black Diamond Therapeutics's novel EGFR inhibitor shows promise in addressing resistance mutations in NSCLC and glioblastoma.

The spinout, dubbed Antares Therapeutics, will be fueled by a $177 million series A round co-led by Omega Funds, Atlas ...

Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not ...

Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events ...

Asandeutertinib is a derivative of Tagrisso designed to avoid certain toxic side effects in patients with EGFR-mutated NSCLC.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', 6990.HK) today announced that results from its ...

New findings from the CONFIDENCE trial show that combination therapy with finerenone and empagliflozin leads to significantly ...